Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $5.4 million.

  • Lipocine's Shares Outstanding (Weighted Average) rose 121.93% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 121.93%. This contributed to the annual value of $5.3 million for FY2024, which is 131.48% up from last year.
  • As of Q3 2025, Lipocine's Shares Outstanding (Weighted Average) stood at $5.4 million, which was up 121.93% from $5.4 million recorded in Q2 2025.
  • Lipocine's Shares Outstanding (Weighted Average)'s 5-year high stood at $88.3 million during Q1 2022, with a 5-year trough of $5.2 million in Q4 2022.
  • For the 5-year period, Lipocine's Shares Outstanding (Weighted Average) averaged around $26.7 million, with its median value being $5.3 million (2024).
  • Per our database at Business Quant, Lipocine's Shares Outstanding (Weighted Average) soared by 9803.16% in 2021 and then tumbled by 9407.22% in 2023.
  • Quarter analysis of 5 years shows Lipocine's Shares Outstanding (Weighted Average) stood at $86.9 million in 2021, then crashed by 93.98% to $5.2 million in 2022, then grew by 0.73% to $5.3 million in 2023, then grew by 1.31% to $5.3 million in 2024, then increased by 1.39% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $5.4 million for Q2 2025, and $5.3 million during Q1 2025.